Search research articles
Contact Us
Filters
Showing results (11-20 of 19) with videos related to
Page
of 2
Sort By:
You have reached the last page of results.
This site can display upto 19 results.
Clinical Pharmacology and Therapeutics
|
September 20, 2016
PIPELINEs: Creating Comparable Clinical Knowledge Efficiently by Linking Trial Platforms
M R Trusheim, A A Shrier, Z Antonijevic, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 12, 2007
A phase I and pharmacokinetic study of lapatinib in combination with infusional 5-fluorouracil, leucovorin and irinotecan
R S Midgley, D J Kerr, K T Flaherty, et al.
British Journal of Cancer
|
August 2, 2006
Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis
T Eisen, T Ahmad, K T Flaherty, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 30, 2017
Vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 study
P B Chapman, C Robert, J Larkin, et al.
Oncogene
|
June 16, 2015
Fibronectin induction abrogates the BRAF inhibitor response of BRAF V600E/PTEN-null melanoma cells
I V Fedorenko, E V Abel, J M Koomen, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 11, 2019
Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric/gastroesophageal junction (GEJ) adenocarcinomas: results from the NCI-MATCH trial (EAY131) subprotocol Q
K L Jhaveri, X V Wang, V Makker, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 6, 2017
Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study
G V Long, K T Flaherty, D Stroyakovskiy, et al.
NPJ Precision Oncology
|
March 2, 2022
Crizotinib in patients with tumors harboring ALK or ROS1 rearrangements in the NCI-MATCH trial
A S Mansfield, Z Wei, R Mehra, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 20, 2024
A model for decoding resistance in precision oncology: acquired resistance to FGFR inhibitors in cholangiocarcinoma
L Goyal, D DiToro, F Facchinetti, et al.
Page
of 2
Search research articles
Search
Showing results (11-20 of 19) with videos related to
Sort By:
Page
of 2
You have reached the last page of results.
This site can display upto 19 results.
Clinical Pharmacology and Therapeutics
|
September 20, 2016
PIPELINEs: Creating Comparable Clinical Knowledge Efficiently by Linking Trial Platforms
M R Trusheim, A A Shrier, Z Antonijevic, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 12, 2007
A phase I and pharmacokinetic study of lapatinib in combination with infusional 5-fluorouracil, leucovorin and irinotecan
R S Midgley, D J Kerr, K T Flaherty, et al.
British Journal of Cancer
|
August 2, 2006
Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis
T Eisen, T Ahmad, K T Flaherty, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 30, 2017
Vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 study
P B Chapman, C Robert, J Larkin, et al.
Oncogene
|
June 16, 2015
Fibronectin induction abrogates the BRAF inhibitor response of BRAF V600E/PTEN-null melanoma cells
I V Fedorenko, E V Abel, J M Koomen, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 11, 2019
Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric/gastroesophageal junction (GEJ) adenocarcinomas: results from the NCI-MATCH trial (EAY131) subprotocol Q
K L Jhaveri, X V Wang, V Makker, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 6, 2017
Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study
G V Long, K T Flaherty, D Stroyakovskiy, et al.
NPJ Precision Oncology
|
March 2, 2022
Crizotinib in patients with tumors harboring ALK or ROS1 rearrangements in the NCI-MATCH trial
A S Mansfield, Z Wei, R Mehra, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 20, 2024
A model for decoding resistance in precision oncology: acquired resistance to FGFR inhibitors in cholangiocarcinoma
L Goyal, D DiToro, F Facchinetti, et al.
Page
of 2